Literature DB >> 15371635

Vascular endothelial toxicity induced by HIV protease inhibitor: evidence of oxidant-related dysfunction and apoptosis.

Reshma S Baliga1, Cynthia Liu, Dale G Hoyt, Alysia A Chaves, John A Bauer.   

Abstract

HIV-protease inhibitor (HIV-PI) drugs are critical for highly active antiretroviral therapy (HAART) efficacy, but several recent reports have suggested that metabolic and/or cardiovascular toxicities are associated with these drugs. Given the importance of the HIV-PI drug class and the widespread and chronic use of these agents in an expanding patient population, further understanding of this potential drug toxicity is imperative. Here, we investigated a role for direct endothelial toxicity induced by saquinavir (SAQ), the first HIV-PI drug marketed in the United States and still an important component of HAART therapies. In initial studies using isolated vascular tissues, we observed selective impairment of endothelium-dependent vasodilation with no effect on contractile responses. Subsequent studies using human endothelial cells in culture at clinically relevant concentrations (5 and 10 microM, 2-48 h) demonstrated concentration-dependent increases in cell death, mainly via apoptosis rather than necrosis (determined via Annexin-V positive membrane labeling). Live cell imaging also demonstrated increased intracellular oxidant production (as measured by DCF fluorescence), which could be abrogated by incubation with the antioxidant N-acetylcysteine (NAC). NAC also prevented SAQ- induced apoptotic cell death. These data demonstrate that SAQ has direct toxicological effects on endothelial cells, and that the toxicity apparently involves apoptotic pathway activation via reactive oxygen and/or nitrogen species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15371635     DOI: 10.1385/ct:4:2:199

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  8 in total

1.  Increased myocardial prevalence of C-reactive protein in human coronary heart disease: direct effects on microvessel density and endothelial cell survival.

Authors:  Mandar S Joshi; Liyue Tong; Angela C Cook; Brandon L Schanbacher; Hong Huang; Bing Han; Leona W Ayers; John Anthony Bauer
Journal:  Cardiovasc Pathol       Date:  2012-01-28       Impact factor: 2.185

2.  State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary.

Authors:  Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Judith S Currier; Jens D Lundgren; Michael P Dubé; Steven E Lipshultz; Priscilla Y Hsue; Kathleen Squires; Morris Schambelan; Peter W F Wilson; Kevin E Yarasheski; Colleen M Hadigan; James H Stein; Robert H Eckel
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

Review 3.  The spectrum of atherosclerotic coronary artery disease in HIV patients.

Authors:  Abdul Hakeem; Sabha Bhatti; Mehmet Cilingiroglu
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

4.  Association of antiretroviral therapy with brain aging changes among HIV-infected adults.

Authors:  Virawudh Soontornniyomkij; Anya Umlauf; Benchawanna Soontornniyomkij; Ben Gouaux; Ronald J Ellis; Andrew J Levine; David J Moore; Scott L Letendre
Journal:  AIDS       Date:  2018-09-10       Impact factor: 4.177

5.  Hyperglycemia exacerbates antiretroviral drug combination induced blood-brain barrier endothelial toxicity.

Authors:  Shikha Prasad; Ravi K Sajja; Mohammad A Kaisar; Luca Cucullo
Journal:  Neurotoxicology       Date:  2016-06-23       Impact factor: 4.294

Review 6.  Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.

Authors:  Ankit Shah; Mohitkumar R Gangwani; Nitish S Chaudhari; Alexy Glazyrin; Hari K Bhat; Anil Kumar
Journal:  Neurotox Res       Date:  2016-06-30       Impact factor: 3.911

Review 7.  The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction.

Authors:  Erik R Kline; Roy L Sutliff
Journal:  J Investig Med       Date:  2008-06       Impact factor: 2.895

8.  Premature and accelerated aging: HIV or HAART?

Authors:  Reuben L Smith; Richard de Boer; Stanley Brul; Yelena Budovskaya; Hans van Spek
Journal:  Front Genet       Date:  2013-01-28       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.